Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Somatostatin Receptor Ligand. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 known ✓ | P31391 | 16/20 | 0.79 |
| ▸ | SSTR2 known ✓ | P30874 | 12/20 | 0.79 |
| ▸ | SSTR5 known ✓ | P35346 | 12/20 | 0.79 |
| ▸ | SSTR3 known ✓ | P32745 | 11/20 | 0.79 |
| ▸ | SSTR1 known ✓ | P30872 | 9/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368491 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| Somatostatin Receptor Ligand SCHEMBL29386529 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| Somatostatin Receptor Ligand SCHEMBL12548326 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| Somatostatin Receptor Ligand SCHEMBL31432768 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| Somatostatin Receptor Ligand SCHEMBL16062971 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| Somatostatin SCHEMBL29350200 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| Somatostatin Receptor Ligand SCHEMBL8482 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| Somatostatin Receptor Ligand SCHEMBL3046327 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| Somatostatin SCHEMBL21361053 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 | |
| Somatostatin Receptor Ligand SCHEMBL16186775 | 0.96 | SSTR4 (0.83) | SSTR4SSTR2SSTR5SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10933142-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS LTD (GB) | 2021-03-02 | — | — | US | disclosed |
| US-20200108150-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL BUSINESS LTD (GB) | 2020-04-09 | — | — | US | disclosed |
| US-10548982-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS LTD (GB) | 2020-02-04 | — | — | US | disclosed |
| US-20190142950-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| US-10174094-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20160176942-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS PLC (GB) | 2016-06-23 | — | — | US | disclosed |
| US-9295729-B2 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2016-03-29 | — | — | US | disclosed |
| EP-2889624-A2 | Reversible covalent linkage of functional molecules | UCL Business PLC (GB) | 2015-07-01 | — | — | EP | disclosed |
| EP-2549276-B1 | Reversible covalent linkage of functional molecules | UCL BUSINESS PLC (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2464654-B1 | THIOL PROTECTING GROUP | UCL BUSINESS PLC (GB) | 2014-10-08 | — | — | EP | disclosed |
| EP-2549276-A2 | Reversible covalent linkage of functional molecules | UCL Business PLC (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120190814-A1 | Thiol Protecting Group | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190124-A1 | Reversible Covalent Linkage of Functional Molecules | UCL BUSINESS LTD (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190579-A1 | Functionalisation of Solid Substrates | UCL BUSINESS PLC (GB) | 2012-07-26 | — | — | US | disclosed |
| EP-2464972-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL Business PLC (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-2464654-A2 | THIOL PROTECTING GROUP | UCL Business PLC (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-2464974-A1 | FUNCTIONALISATION OF SOLID SUBSTRATES | UCL Business PLC (GB) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011018613-A1 | FUNCTIONALISATION OF SOLID SUBSTRATES | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011018611-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011018612-A2 | THIOL PROTECTING GROUP | UCL BUSINESS PLC (GB) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174094-B2 | Reversible covalent linkage of functional molecules | F12, F13A1, F2 | SSTR4 2494/4885SSTR2 2539/4885SSTR5 1972/4885 |
| US-20120190124-A1 | Reversible Covalent Linkage of Functional Molecules | F12, F13A1, F2 | SSTR4 2494/4885SSTR2 2539/4885SSTR5 1972/4885 |
| US-20190142950-A1 | Reversible Covalent Linkage of Functional Molecules | F12, F13A1, F2 | SSTR4 2494/4885SSTR2 2539/4885SSTR5 1972/4885 |
| US-20120190579-A1 | Functionalisation of Solid Substrates | XDH, SPR, DAO | SSTR4 1221/4885SSTR2 3049/4885SSTR5 1491/4885 |
| US-20160176942-A1 | Reversible Covalent Linkage of Functional Molecules | F12, F13A1, F2 | SSTR4 2494/4885SSTR2 2539/4885SSTR5 1972/4885 |
| US-10548982-B2 | Reversible covalent linkage of functional molecules | F12, F13A1, F2 | SSTR4 2494/4885SSTR2 2539/4885SSTR5 1972/4885 |
| US-10933142-B2 | Reversible covalent linkage of functional molecules | F12, F13A1, F2 | SSTR4 2494/4885SSTR2 2539/4885SSTR5 1972/4885 |
| US-20200108150-A1 | REVERSIBLE COVALENT LINKAGE OF FUNCTIONAL MOLECULES | F12, F13A1, F2 | SSTR4 2477/4885SSTR2 2497/4885SSTR5 1927/4885 |
| US-20120190814-A1 | Thiol Protecting Group | TXN, PRDX3, TST | SSTR4 4464/4885SSTR2 4640/4885SSTR5 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.